Evidence map›Paper›PMID 28774800›Full record

ArticleAntiviral research2017

Highlights of the 30th International Conference on Antiviral Research.

Graciela Andrei, Kara Carter, Zlatko Janeba, Aruna Sampath, Luis M Schang, E Bart Tarbet, R Anthony Vere Hodge, Mike Bray, José A Esté

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Antiviral research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Meeting report: 31Antiviral research · 2018
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 4 countries.

Graciela AndreiKU Leuven, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Kara CarterSanofi, 270 Albany Street, Cambridge, MA 02139, USA.
Zlatko JanebaThe Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Flemingovo nám. 2, CZ-16610 Prague 6, Czech Republic.
Aruna SampathEmergent BioSolutions, 400 Professional Drive, Ste 400, Gaithersburg, MD 20879, USA.
Luis M SchangBaker Institute, Cornell University College of Veterinary Medicine, 235 Hungerford Hill Road, Ithaca, NY 14853, USA.
E Bart TarbetInstitute for Antiviral Research, Utah State University, Logan, UT, USA.
R Anthony Vere HodgeVere Hodge Antivirals Ltd, Old Denshott, Leigh, Reigate, Surrey, UK.
Mike BrayChevy Chase, MD, USA.
José A EstéAIDS Research Institute - Irsicaixa, Hospital Germans Trias i Pujol, Universitat Autónoma de Barcelona, Canyet s/n, Badalona, Spain; International Society for Antiviral Research, Spain. Electronic address: jaeste@irsicaixa.es.
Cornell University · USCzech Academy of Sciences, Institute of Organic Chemistry and Biochemistry · CZEmergent BioSolutions (United States) · USRega Institute for Medical Research · BESanofi (United States) · USUniversitat Autònoma de Barcelona · ESUtah State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 30th International Conference on Antiviral Research (ICAR) was held in Atlanta, GA, USA from May 18 to 21, 2017. This report provides an account of award lectures, invited keynote addresses and oral presentations during the meeting. The 2017 Gertrude Elion Memorial Lecture Award by Michael Sofia highlighted one of the most important accomplishments in recent drug discovery in antiviral research, the identification of the hepatitis C virus direct-acting antiviral sofosbuvir and new alternatives to combat hepatitis B virus (HBV) infection. The Antonín Holý Lecture Award by David Chu on medicinal chemistry provided an overview of early developments of nucleoside analogs for the treatment of HIV and varicella zoster virus infection and how this knowledge serves to develop new drugs targeting HBV. Priscilla Yang gave the first ISAR Women in Science lecture. She reported on pharmacological validation of new antiviral targets for dengue, Zika and other flaviviruses. The William Prusoff Young Investigator Lecture Award by Maaike Everts described the Alabama Drug Discovery Alliance and the Antiviral Drug Discovery and Development Consortium, and how they are helping to accelerate the development of new antivirals. The 30th ICAR was a success in promoting new discoveries in antiviral drug development and research. The 31st ICAR will be held in Porto, Portugal, June 11-15, 2018.

Indexed as

Antiviral AgentsChemistry, PharmaceuticalDrug DiscoveryDengueHepatitis BHumansZika Virus InfectionAntiviral Agents

Identifiers

PMID28774800
PMCPMC7127040
OpenAlexW2740025293

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.